Two Decades of Driving Treatment Development

Today's treatments are possible because friends like you support alopecia areata research and advocacy.

www.naaf.org/research
In June 2022, the U.S. Food and Drug Administration announced Olumiant™ as the first ever drug approved for the treatment for adults living with severe alopecia areata. In June 2023, a second drug, Litfulo™, was approved for the treatment of those 12+. These treatments are the culmination of BIG thinking combined with BIG action by the National Alopecia Areata Foundation (NAAF) community. It represents the successful outcome of two decades of focused effort by NAAF, the researchers NAAF funds and collaborates with, our industry partners, and our patient advocates--all made possible by NAAF donors.